title: Assessment of the impact of new UK guidelines on the management of aromatase inhibitor-associated bone loss.
authors.forename: E
authors.initials: E
authors.lastname: Sowden
authors.forename: B
authors.initials: B
authors.lastname: Evans
authors.forename: C M
authors.initials: CM
authors.lastname: Greenbank
authors.forename: M
authors.initials: M
authors.lastname: Bukhari
authors.forename: J P
authors.initials: JP
authors.lastname: Halsey
mesh_terms: D000328:Adult; D000368:Aged; D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D004164:Diphosphonates / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D019983:Guideline Adherence; D017408:Guidelines as Topic; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced / Q000191:economics / Q000517:prevention & control*; D006113:United Kingdom
chemical_list: D047072:Aromatase Inhibitors; D004164:Diphosphonates